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ABSTRACT 
Background: Previous studies suggested that alterations in serum cortisol levels may play a role 
in the pathophysiology of schizophrenia. Imbalance in serum cortisol levels may be related to 
responsivity to antipsychotic treatment. 
Aim: To compare serum cortisol levels between patients with schizophrenia and healthy controls 
and to evaluate hormone association with psychopathology and response to antipsychotics in 
patients with schizophrenia.  
Material and Methods: This clinical prospective study included 60 patients with schizophrenia 
and 40 healthy age and sex matched controls. All patients experienced an acute exacerbation of 
the illness (PANSS: P1 and P3 ≥ 4). Clinical evaluation of patients was performed using the 
Positive and Negative Symptom Scale. A questionnaire for socio-demographic and clinical data 
collection was used. For the purposes of the study, the examined group was divided in two 
subgroups: responders and nonresponders. Serum cortisol and DHEA-S levels were measured at 
baseline in all participants and after 3 and 6 weeks of the antipsychotic treatment in patients with 
schizophrenia. 
Results: Patients with schizophrenia had significantly higher serum cortisol levels compared 
with control group. Responders had significantly higher serum cortisol levels compared with 
nonresponders. From the three analyzed factors (serum cortisol, DHEA-S and cortisol/DHEA-S 
ratio), only serum cortisol was significant factor for antipsychotic treatment response. 
Responders group had significant correlation between serum cortisol and PANSS positive scale 
score.  
Conclusion: Elevated serum cortisol levels may be considered as a biomarker for the diagnosis 
of schizophrenia and may be used as a significant predictor for positive response to antipsychotic 
treatment in schizophrenia patients with acute exacerbation. Serum cortisol levels are associated 
with severity of specific symptoms in patients with schizophrenia according to their responsivity 
to antipsychotic treatment. 
 
Keywords: schizophrenia, cortisol, psychopathology, antipsychotic treatment response  
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INTRODUCTION 
 Schizophrenia is a chronic and disabling mental disorder characterized by positive, 
negative and mood symptoms, disturbed coping abilities with elevated distress and a significant 
decline in cognition, quality of life and psychosocial functioning. Understanding the etiology and 
pathogenesis of schizophrenia is a major challenge facing psychiatry (Ritsner, 2010). 
 Hypothalamic-pituitary-adrenal (HPA) axis abnormalities play a key role in the etiology 
and pathogenesis of severe psychiatric disorders (Raison et al, 2003). The HPA axis is activated 
by all sorts of stressors, and this fact has represented the rationale for investigations into HPA 
axis function in schizophrenia, a disorder where stress could play a pivotal role in its onset and 
exacerbation (Hori et al, 2012). The behavioral and biological data from the previous researches 
indicated that stress worsens schizophrenic symptoms and that the disorder is associated with a 
heightened response to stressors (Ritsner et al, 2004). A neural mechanism for these phenomena 
is suggested by the augmenting effect of the HPA system on dopamine synthesis and receptors. 
Assuming that the diathesis for schizophrenia involves an abnormality in dopamine receptors, it 
is proposed that the HPA axis acts to potentiate schizophrenic systems by means of its effects on 
dopamine (Yilmaz et al, 2007).  
 HPA axis abnormalities may cause an increase in the baseline cortisol level (Yildirim et 
al, 2011). It has been demonstrated that serum baseline cortisol levels are increased in patients 
with schizophrenia (Hori et al, 2012; Yildirim et al, 2011; Gallagher et al, 2007; Yilmaz et al, 
2007; Zhang et al, 2005; Ryan et al, 2004; Walder et al, 2000; Kaneko et al, 1992). However 
there are also other studies with contrary findings (Beyazyüz et al, 2014; Ritsner et al, 2004; 
Taherianfard et al, 2004; Kaneda et al, 2002). Authors of one study reported elevated serum 
cortisol levels in schizophrenic patients and their first-degree relatives and they suggested that 
similar physiopathologic processes occurring in the same genetic background might have a role 
in this increase (Yildirim et al, 2011).   
 Previous studies have suggested that alterations in cortisol levels may play a role in the 
pathophysiology of schizophrenia (Garner et al, 2011; Yildirim et al, 2011; Shulman et al, 2005). 
Serum cortisol levels may be used as a biological marker for the diagnosis of schizophrenia; 
however, further studies with larger sample sizes are warranted to support this finding (Yildirim 
et al, 2011). 
  Many researchers investigated association between serum cortisol and psychopathology 
in patients with schizophrenia. In some studies cortisol secretion was primarily associated with 
more severe positive symptoms (Walder et al, 2000; Kaneko et al, 1992; Rybakowski et al, 
1991), whereas in others it was associated with higher ratings of negative symptoms (Zhang et 
al, 2005; Shirayama et al, 2002; Tandon et al, 1991). It has been suggested that the relation 
between cortisol levels and symptoms severity is due to the augmenting effects of cortisol on 
dopamine activity (Walker et al, 1997). Authors of one prospective study investigated circulating 
cortisol in patients with first episode psychosis and they concluded that decreases in cortisol over 
time was directly related to the improvement in depressive, negative and psychotic symptoms 
(Garner et al, 2011).   
 Authors of one study investigated association between serum cortisol, DHEA-S levels, as 
well as their molar ratios with PANSS dimensions in schizophrenic patients with different 
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response to antipsychotic treatment (Ritsner et al, 2005). They suggested that imbalance in serum 
cortisol and DHEA-S may be related to pathophysiological processes in schizophrenia, 
particularly to responsivity to antipsychotic treatment. Elevated cortisol levels and an elevated 
cortisol-DHEA(S) ratio have been shown to be predictive of a positive response to antipsychotic 
treatment according to these authors. 
 
The aim of the study was to compare serum cortisol levels between patients with schizophrenia 
and healthy control subjects and to evaluate the correlation between hormone levels with 
psychopathology and response to antipsychotics in schizophrenic patients with acute 
exacerbation.  
 
MATERIAL AND METHODS 
 In this clinical prospective study by its design were included 60 patients with 
schizophrenia and 40 healthy age and sex matched control subjects.  
 Examined group consisted of sixty patients with schizophrenia from both genders, age 
18-50, treated as inpatients or outpatients at the University Psychiatry Clinic, Skopje, 
Macedonia. All patients experienced an acute exacerbation of the illness (PANSS: P1-Delusions 
and P3-Hallucinatory behavior ≥ 4). Patients who suffered from major physical illness, drug or 
alcohol abuse, epilepsy and other organic brain syndromes were not included. All patients 
underwent physical examination and routine laboratory tests to rule out physical illness. Clinical 
evaluation of patients was performed using the Positive and Negative Symptom Scale (Kay et al, 
1987). Non-standardized questionnaire was used for socio-demographic and clinical data 
collection.  
 For the purposes of this study, the examined group was divided in two subgroups: 
1. subgroup of subjects suffering from schizophrenia classified as responders who had no 
ratings of >3 on items P1,P2, P3, P5 and P6 of the PANSS. 
2. subgroup of subjects suffering from schizophrenia who did not meet these criteria were 
defined as nonresponders. 
 Control group consisted of forty healthy age and sex matched control subjects. All were 
physically healthy and had no personal or family history of psychiatric disorder.  
 All participants in the study provided written informed consent to participate in this 
prospective study after having received a detailed explanation of the study procedures. The study 
was approved by the Ethics Committee of Medical University in Skopje and the Board of the 
University Clinic of Psychiatry. 
 
Steroid determination 
 Serum cortisol and DHEA-S levels were measured in the Institute of clinical 
biochemistry at the Medical University in Skopje, Macedonia. Serum samples of cortisol and 
DHEA-S were collected between 8 a.m. and 9 a.m. hours after 20 min of rest. All participants 
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were instructed to abstain from unusual physical activity or stress for a period of 24 h prior to 
blood sampling. Blood samples were collected at baseline in all participants and after 3 and 6 
weeks of the antipsychotic treatment in patients with schizophrenia. Cortisol and DHEA-S levels 
were measured by the IMMULITE 2000, competitive chemiluminescent enzime immunoassay. 
 
 
Statistical analysis 
 
 Several statistical methods have been used for the statistical analysis of the data obtained 
in the course of the study: non-parametric methods (Chi-square test, Mann-Whitney U test, 
Friedman ANOVA) and parametric methods (t-test for independent samples). Correlation 
between parameters was examined with Pearson and Spearman Rank correlation coefficients. 
From the multivariate methods MANOVA and Binary Logistic Regression were used. Values of 
p < 0,05 were considered statistically significant. 
 
 
RESULTS 
 Patients with schizophrenia had significantly higher mean serum cortisol level in 
comparison to the control group (Table 1). 
 
Table 1. Serum levels of cortisol in the examined and control group 
Hormone Examined group Control group test p-value 
Cortisol 555,7±159,8 351,7±172,1 t=6,07 0,00000 
t (t-test for independent samples) 
 The two subgroups of the examined group classified as responders and nonresponders did 
not significantly differ between themselves in terms of gender (men/women: 29/8 and 15/8 
respectively; Pearson Chi-square=1,26 df=1, p=0,26), age (t= 0,34  p=0,73), marital status 
(Pearson Chi-square=1,41 df=2 p=0,49), education (Pearson Chi-square=4,21 df=3 p=0,24), age 
of onset of the disorder (Z=0,15; p=0,88), duration of illness (Z=0,32; p=0,75), number of 
relapses (Z=0,11; p=0,9), number of hospital treatments (Z=0,68; p=0,49) and the type of 
antipsychotic agents - typical/atypical (Pearson Chi-square=0,86 df=1 p=0,35). 
 Table 2 shows serum cortisol levels in the subgroup of responders compared with the 
subgroup of nonresponders at baseline assessment point. 
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Table 2. Serum cortisol levels at baseline in responders and nonresponders 
Hormone Responders 
N=37 
Nonresponders 
N=23 
test p-value 
Cortisol 640,6±116,4 419,1±121,2 7,05 0,000000 
 
 Across all three assessment points (baseline, after 3 and 6 weeks) the responders had a 
significantly higher serum cortisol levels compared with nonresponders (MANOVA, Hotelling-
Lawley test, F=16,24; df=6,226; p=0,000).  
 In the responders subgroup we found significant correlation between the duration of the 
illness and serum cortisol levels (r= 0,4; p=0,014). This correlation is positive, thus higher serum 
cortisol levels are associated with longer duration of the disorder. 
 In the nonresponders subgroup we found negative significant correlation between the age 
of onset of the disorder and serum cortisol, therefore younger age of the onset is associated with 
higher serum cortisol levels (r= -0,41; p=0,05). 
 To test the assumption that elevated serum cortisol levels may be related to positive 
response to antipsychotic treatment during acute exacerbation of schizophrenia, we used Binary 
Logistic Analysis to determine the predictive value of serum cortisol, DHEA-S and 
cortisol/DHEA-S ratio for responding to antipsychotic therapy (Table 3). 
 
Table 3. Binary Logistic Analysis (serum cortisol, DHEA-S and cortisol/ DHEA-S ratio at 
baseline) 
-2 Log likelihood =39,893  Nagelkerke R Sduare=0,661 percent correct=85,0 
  
 
B 
 
 
S.E. 
 
 
Wald 
 
 
df 
 
 
Sig. 
 
 
EXP(B) 
95,0 % C.I.for 
EXP(B) 
Lower Upper 
Cortisol -0,014 0,005 8,513 1 0,004 0,986 0,977 0,995 
DHEA-S -0,008 0,005 2,558 1 0,110 0,992 0,981 1,002 
[SYLWAN., 159(4)]. ISI Indexed 427
Cortisol/DHEA-
S 
-0,188 0,395 0,227 1 0,633 0,828 0,382 1,796 
Gender 1,241 1,240 1,002 1 0,317 3,459 0,305 39,301 
Constant 9,679 2,624 13,603 1 0,000 15978,441   
Dependent variable: without positive response/with positive response 
 
 From the three analyzed factors, only serum cortisol was significant factor for 
antipsychotic treatment response, respectively elevated cortisol levels were associated with 
positive response to antipsychotic therapy. 
 According to the PANSS scores the subgroup of responders scored significantly higher 
on positive PANSS scale (F=6,06;  df=1  58; p=0,017), delusions (F=7,41;  df=1  58; p=0,009) 
and suspiciousness (F=12,509;  df=1  58; p=0,001) compared with the subgroup of 
nonresponders at baseline. The differences between the subgroups according hallucinatory 
behavior, hostility and negative scale were not statistically significant.   
 The subgroup of responders showed greater reduction of the PANSS positive (Graph 1) 
and PANSS negative scale scores (Friedman ANOVA ANOVA Chi Sqr. p =0 00000) across all 
three assessment points (baseline, after 3 and 6 weeks of antipsychotic therapy) than the 
subgroup of nonresponders. 
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Graph 1. PANSS positive scale scores across three assessment points in responders and 
nonresponders 
 
  
 Correlation between serum cortisol levels with PANSS scores across all three assessment 
points in the two subgroups was examined with Spearman Rank Order Correlations. The results 
of examined correlation between hormone levels and PANSS scores in the subgroup of 
responders indicated statistically significant correlation between serum cortisol and PANSS 
positive scale score at the third assessment point (Table 4). The correlation is negative, 
accordingly higher serum cortisol levels significantly correlated with lower PANSS positive 
scale score. 
 
Table 4. Responders - correlation serum cortisol/PANSS third assessment point 
Cortisol-third assessment 
point 
Spearman Rank Order 
Correlations 
p-value 
PANSS - delusions -0,25 > 0,05 
PANSS - hallucinatory 
behavior 
-0,086 > 0,05 
PANSS - suspiciousness /  
0
5
10
15
20
25
30
responders nonresponders
27,16 
24,52 
22,76 22,13 
15,67 17,78 
PANSS positive  
(mean) 
Baseline After 3 weeks After 6 weeks
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PANSS - hostility 0,05 > 0,05 
PANSS - positive scale -0,35 <0,05 
PANSS - negative scale -0,022 > 0,05 
 
 Examined correlation between serum cortisol levels with PANSS scores across all three 
assessment points in the subgroup of nonresponders showed statistically significant correlation 
between cortisol and item delusions from the PANSS positive scale at the baseline (R=0,45; 
p<0,05). This correlation is positive, respectively higher serum cortisol levels are associated with 
higher scores for delusions. 
 
DISCUSSION 
 The assumption that alterations in serum cortisol levels may have a role in changes in 
clinical presentation of several neuropsychiatric disorders, including schizophrenia, has been 
emphasized (Yildirim et al, 2011). 
 Authors of one study presented increased activity of cortisol metabolism in patients with 
schizophrenia compared to healthy controls and suggest that increased systemic cortisol 
metabolism is involved in the pathophysiology and stress vulnerability in this severe disorder 
(Steen et al, 2011). 
 Our study showed that plasma cortisol levels were significantly elevated in the group of 
patients with schizophrenia compared with controls, which is in agreement with the results of 
most of the studies (Hori et al, 2012; Yildirim et al, 2011; Gallagher et al, 2007; Yilmaz et al, 
2007; Zhang et al, 2005; Muck-Seler D et al, 2004; Ryan et al, 2004; Walder et al, 2000; Kaneko 
et al, 1992). However there are studies reporting no significant differences between the 
schizophrenic patients and healthy controls in terms of cortisol levels (Beyazyüz et al, 2014; 
Ritsner et al, 2004; Kaneda et al, 2002), as well as lower cortisol levels in patients with 
schizophrenia (Taherianfard et al, 2004). 
 Our results showed that elevated serum cortisol levels in patients with schizophrenia may 
play a role in the pathophysiology of schizophrenia and may be considered as a biomarker for 
schizophrenia. 
 In the last 3 decades, several authors have posited a link between neuroactive steroids and 
the pathophysiology or therapeutics of schizophrenia (Beyazyüz et al, 2014). 
 Studies evaluating the association between serum cortisol and psychopathology in 
patients with schizophrenia present a variety of results. Authors of some previous studies found 
positive correlation between cortisol levels and negative symptoms (Zhang et al, 2005; 
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Shirayama et al, 2002; Newcomer et al, 1991; Tandon et al, 1991). In contrast, some other 
studies found a correlation between serum cortisol and positive symptoms (Walder et al, 2000; 
Kaneko et al, 1992; Rybakowski et al, 1991; Keshavan et al, 1989). Authors of one study did not 
find significant correlation between serum cortisol and symptom dimensions assessed with the 
PANSS (Hori et al, 2012). Authors of another study found positive correlation between cortisol 
levels and the rating of positive, disorganized and overall symptom severity, but not with 
negative symptoms (Walder et al, 2000). 
 Authors of one study investigated serum cortisol in two groups of schizophrenia patients 
divided according to their responsivity to antipsychotic treatment (Ritsner et al, 2005). Their 
results indicate that responders had significantly higher basal levels of cortisol compared with 
nonresponders. They also examined correlation between changes in serum values of cortisol with 
changes in PANSS dimensions. They demonstrated that among responders increased serum 
cortisol concentrations significantly correlated with improvement in activation and PANSS total 
score. Among nonresponders no significant correlation was observed between changes in any 
hormonal measures and symptom severity according to this study. 
 According to the PANSS scores our study showed that responders scored significantly 
higher on positive PANSS scale, delusions and suspiciousness compared with nonresponders 
which coincided with the results of other study (Ritsner et al, 2005). In our study responders 
showed greater reduction of the PANSS positive and negative scale scores across all three 
assessment points compared with nonresponders. Authors of one other study showed that 
responders had greater reduction in the PANSS total score than nonresponders (Ritsner et al, 
2005). 
 Examinated association between serum cortisol and psychopathology in responders 
subgroup in our study showed significant correlation between serum cortisol and PANSS 
positive scale score. 
 Investigated correlation between serum cortisol and psychopathology in the subgroup of 
nonresponders showed statistically significant correlation between serum cortisol and delusions.  
 Our results suggest that serum cortisol levels are associated with severity of specific 
symptoms in patients with schizophrenia according to their responsivity to antipsychotic 
treatment. 
 The present study also evaluated association between serum cortisol levels and response 
to antipsychotic treatment in schizophrenic patients with acute exacerbation. At baseline 
assessment point the subgroup of responders showed significantly higher serum cortisol levels 
compared with the subgroup of nonresponders. Across all three assessment points the responders 
had a significantly higher serum cortisol levels compared with nonresponders which is consistent 
with the results of other study (Ritsner et al, 2005). Tested predictive value of serum cortisol, 
DHEA-S and cortisol/DHEA-S ratio for responding to antipsychotic therapy in our study showed 
that only serum cortisol is a significant predictor for responsivity to antipsychotic treatment in 
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schizophrenia patients with acute exacerbation, respectively elevated serum cortisol levels are 
related to positive response to antipsychotic therapy. Authors of one previously mentioned study 
provided evidence that elevated serum cortisol and cortisol/DHEA-S ratio may serve as markers 
of biological mechanisms that are involved in responsivity of schizophrenia patients to 
antipsychotic treatment (Ritsner et al, 2005). 
 Limited number of studies that investigate correlation between serum cortisol levels with 
psychopathology in patients with schizophrenia according to their responsivity to antipsychotic 
therapy as well as hormone predictive value for antipsychotic response are the reasons for 
required similar future researches. 
 
CONCLUSIONS 
 Elevated serum cortisol levels may be considered as a specific endocrine marker for the 
diagnosis of schizophrenia. 
 The subgroup of responders had a significantly higher serum cortisol levels compared 
with the subgroup of nonresponders. 
 Elevated serum cortisol may be used as a significant predictor for positive response to 
antipsychotic treatment in schizophrenia patients with acute exacerbation. 
 Responders scored significantly higher on positive PANSS scale, delusions and 
suspiciousness compared with nonresponders. 
 Responders showed greater reduction of the PANSS positive and negative scale scores 
across all three assessment points compared with nonresponders. 
 The responders subgroup demonstrated significant correlation between serum cortisol 
and PANSS positive scale score. 
 The subgroup of nonresponders had significant correlation between serum cortisol and 
delusions. 
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